Table 3.

Geometric mean neutralization titres of HPV 16, 18 and 6 L1 antibodies at 18 months after first dose among girls who received three doses (at 1, 60 and 180+ days) and two doses (at 1 and 180+ days) by age.

HPV type	Age group (years)	No. of samples tested	No. of samples with Detectable neutralization antibodies (%)		Geometric mean neutralization titres (95% CI)		Geometric mean ratio (95% CI)a[2-dose/3-dose, 10–14 age group]		Geometric mean ratio (95% CI)b[2-dose, 15–18 age group/3-dose, 15–18 age group]
HPV 16 L1
3-dose (Days 1, 60, 180)	10–14	33	33	(100.0)	14,417	(10,550–19,702)	1.00
	15–18	27	27	(100.0)	6262	(4095–9577)	0.43	(0.36–0.52)	1.00
2-dose (Days 1, 180)	10–14	27	27	(100.0)	10,845	(7556–15,567)	0.75	(0.50–1.12)
	15–18	32	32	(100.0)	9154	(6476–12,940)	0.63	(0.48–0.84)	1.46	(1.08–1.98)
HPV 18 L1
3-dose (Days 1, 60, 180)	10–14	33	33	(100.0)	3296	(2109–5150)	1.00
	15–18	27	26	(96.3)	1003	(690–1459)	0.30	(0.21–0.45)	1.00
2-dose (Days 1, 180)	10–14	27	27	(100.0)	1112	(654–1891)	0.34	(0.20–0.56)
	15–18	32	32	(100.0)	632	(387–1033)	0.19	(0.13–0.28)	0.63	(0.44–0.91)
HPV 6 L1
3-dose (Days 1, 60, 180)	10–14	33	33	(100.0)	19,728	(11,167–34,852)	1.00
	15–18	27	27	(100.0)	9113	(5960–13,932)	0.46	(0.28–0.77)	1.00
2-dose (Days 1, 180)	10–14	27	27	(100.0)	13,369	(8509–21,006)	0.68	(0.52–0.89)
	15–18	32	32	(100.0)	9124	(5765–14,439)	0.46	(0.31–0.68)	1.00	(0.57–1.75)

CI: confidence interval; HPV: human papilloma virus.

^aThe other specified dose schedule and age stratum were non-inferior to the standard 2-dose schedule (Days 1, 180) in girls aged 10–14 years if the lower limit of the 95% CI for the geometric mean ratio was above 0.5 (2-fold difference).

^bThe 2-dose, 15–18 age group was non-inferior to the 3-dose, 15–18 age group if the lower limit of the 95% CI for the geometric mean ratio was above 0.5 (2-fold difference).